RxDoctor Payments Data

Melea McCormick, APRN

Family · Fort Smith, ARNPI 1225722804

Payments from drug & device makers

$2,179in general payments, 2019–2025

Across 79 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$743
  • AbbVie$433
  • Eagle Pharmaceuticals, Inc.$137
  • Astellas Pharma US Inc$125
  • Novo Nordisk$113
  • Amgen$99
  • plus $528 from 16 others

What the payments were for

  • Food & beverage$2,179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,179 in reported general payments places this provider in the 80th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$44,814
Medicare patients
277
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$35,215
EliquisApixaban12$9,902
FarxigaDapagliflozin Propanediol14$9,222
Albuterol Sulfate HfaAlbuterol Sulfate68$1,744
Gabapentin48$898
Ondansetron OdtOndansetron15$728
Atorvastatin Calcium63$627
Hydroxyzine Hcl21$475
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$475
Nebivolol Hcl12$363
Rosuvastatin Calcium19$363
Omeprazole39$352
Ropinirole Hcl28$341
Levothyroxine Sodium38$300
Duloxetine Hcl19$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$47$35,21527 claims
PfizerEliquis$43$9,90212 claims
AstraZenecaFarxiga$743$9,22214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,103 family providers in Arkansas.

Other family in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →